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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food
Allergens (NDA) was asked to deliver an opinion on the safety of Schizochytrium sp. oil as a novel food
(NF) pursuant to Regulation (EU) 2015/2283. Schizochytrium sp. is a single-cell microalga. The strain
FCC- 3204, used by the applicant (Fermentalg), belongs to the species Schizochytrium limacinum. The
NF, an oil rich in docosahexaenoic acid (DHA), is obtained from microalgae after enzymatic lysis. The
applicant proposed to use the NF in infant formulae (IF) and follow-on formulae (FOF). The use level
defined by the applicant was derived from Regulation (EU) 2016/127, which states the mandatory
addition of DHA to IF and FOF at the level of 20–50 mg/100 kcal. The intake of DHA resulting from the
use of the NF in IF and FOF is not expected to pose safety concerns. S. limacinum was attributed the
qualified presumption of safety (QPS) status with the qualification ‘for production purposes only’. Data
provided by the applicant demonstrated the absence of viable cells in the NF. No toxicological studies
were performed with the NF. However, based on the available toxicological data on oils derived from
Schizochytrium sp., the QPS status of the source of the NF, the production process, the composition of
the NF and the absence of viable cells in the NF, the Panel considers there are no concerns with regard to
toxicity of the NF. The Panel concludes that the NF is safe under the proposed conditions of use.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Schizochytrium sp. oil is authorised, in accordance with Regulation (EC) No 258/971, as a novel
food for a number of uses as listed in Commission Implementing Regulation (EU) 2017/24702
establishing the Union list of novel foods in accordance with Regulation (EU) 2015/22833. On 23
January 2019, the company Fermentalg submitted a request to the European Commission in
accordance with Article 10 of Regulation (EU) 2015/2283 for an extension of use of Schizochytrium sp.
oil as a novel food. The applicant requests to extend the use of Schizochytrium sp. oil to additional
food categories, namely, infant and follow-on formulae.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion on Schizochytrium sp. oil.
1.2. Information on existing evaluations and authorisations
Three existing evaluations of the NDA Panel of EFSA need to be mentioned:
• In the Scientific Opinion on Dietary Reference Values for fats (EFSA NDA Panel, 2010), the
Panel set an adequate intake (AI) of 250 mg for eicosapentaenoic acid (EPA) plus
docosahexaenoic acid (DHA) for adults; an AI of 100 mg DHA for infants (> 6 months) and
young children < 24 months; and an increase of 100–200 mg preformed DHA in addition to
the AI for adults as an adequate supply of n-3 long chain polyunsaturated fatty acids (PUFA)
during pregnancy and lactation.
• In the Scientific opinion on nutrient requirements and dietary intakes of infants and young
children in the European Union (EFSA NDA Panel, 2013), the Panel concluded on the levels of
nutrient and energy intakes that are considered adequate for the majority of infants and young
children. In particular, the AI for DHA of 100 mg/day was confirmed for infants and young
children between 6 and 24 months and was also applied to infants of 0–6 months, taking into
account the concentration of essential fatty acids (FAs; including DHA) in human breast milk. It
is noted that EFSA has not set AI for DHA for children after 24 months.
• In the Scientific Opinion on the essential composition of infant and follow-on formulae (EFSA
NDA Panel, 2014), the Panel concluded that DHA should be added to IF and FOF due to its
structural role in the nervous system and the retina and its involvement in normal brain and
visual development. A range for the recommended concentration of DHA in IF and FOF was
derived: from 20 mg/100 kcal (4.8 mg/100 kJ), based on the AI of DHA (100 mg/day) and an
average energy intake of 500 kcal/day, to 50 mg/100 kcal (12 mg/100 kJ) based on the
highest observed DHA concentration in human milk (1% DHA in FAs) and the amount of FA in
human milk.
2. Data and methodologies
2.1. Data
The safety assessment of this NF is based on data supplied in the application and information
submitted by the applicant following EFSA requests for supplementary information. In addition,
information provided by the EFSA Panel on Biological Hazards has also been considered (EFSA BIOHAZ
Panel, 2020).
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in Commission Implementing Regulation (EU) 2017/24694.
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel foods ingredients. OJ L 43, 14.2.1997, p. 1.
2 Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in
accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods. OJ L 351,
30.12.2017, p. 72.
3 Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending
Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the
European Parliament and of the Council and Commission Regulation (EC) No 1852/2001. OJ L 327, 11.12.2015, p. 1.
4 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application.5 As indicated in this guidance, it is the
duty of the applicant to provide all of the available (proprietary, confidential and published) scientific
data, including both data in favour and not in favour of supporting the safety of the proposed NF.
This NF application does not include a request for the protection of proprietary data.
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications5 and the
principles described in the relevant existing guidance documents from the EFSA Scientific Committee.
The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and
in Article 7 of Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risks that might be associated with consumption of the NF under




The NF which is the subject of the application is the ‘DHA-rich oil from Schizochytrium sp. (strain
FCC-3204)’. It is produced by the microalgae Schizochytrium sp. (strain FCC-3204). With reference to
article 3 of the NF Regulation 2015/2283, the NF falls under the category 2(a)(ii): ‘food consisting of,
isolated from or produced from microorganisms, fungi or algae’. The production process involves the
controlled growth of these algae followed by extraction and refinement of the oil produced by the
algae. The oil is a mixture of triglycerides composed of PUFA in which DHA represents more than 55%.
The NF is proposed to be used as an ingredient in infant formulae (IF) and follow-on formulae (FOF).
3.2. Identity of the NF
The NF under assessment in the present application is an oil rich in docosahexaenoic acid (DHA).
Common names to define this NF are ‘DHA-rich oil from Schizochytrium sp.’ or ‘DHA-rich algal oil’. The
oil produced by Fermentalg contains more than 55% DHA.
The NF is isolated from marine microalgae belonging to the genus Schizochytrium. The taxonomic
classification of the microalgae is commonly defined as follows: Kingdom: Chromista; Phylum: Bigyra;
Class: Labyrinthula; Order: Thraustochytriida; Family: Thraustochytriaceae; Genus: Schizochytrium.
Some databases refer to the taxonomy Eukaryota, stramenopiles instead of mentioning the
Kingdom (Chromista) and the Phylum (Bigyra). Nevertheless, this is still leading to the class of
Labyrinthula (https://www.uniprot.org/taxonomy/2163902). Furthermore, the taxonomic classification
of the genus Schizochytrium has been subject to discussions in 2007 (Yokohama and Honda, 2007).
Based on genetic and phenotypic analysis, the authors proposed changes in the classification. The
genus Schizochytrium was amended and new genera such as Aurantiochytrium and Oblongichytrium
were defined. Therefore, the genus Schizochytrium can now also be referred to as Aurantiochytrium.
The applicant specified that the strain used to produce the NF is Schizochytrium sp. FCC-3204. This
strain was obtained without use of mutagenic agents or genetic modifications. ‘FCC 3204’ has been
deposited in the Culture Collection of Algae and Protozoa (CCAP), Scottish Marine Institute (SAMS),
under the reference CCAP 4062/7.
The strain FCC-3204 is a natural variant of the strain FCC-1324, which was found by the applicant
after analysing the FA profiles of a number of different isolates and retained because of its unusually
high DHA levels. The strain FCC-1324 was assessed by the Food Safety Authority of Ireland (FSAI,
2014) and recognised as a valid source to produce the NF ‘Schizochytrium sp. oil’ which is currently
authorised on the Union list following the initial assessment by the UK Advisory Committee in 2002
5 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G, Pentieva
K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M, Salminen S,
Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance on the preparation
and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283. EFSA Journal
2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
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(United Kingdom, 2002). Subsequently, following an assessment by the French Agency for Food,
Environmental and Occupational Health and Safety (Anses, 2018), the DHA-rich oil produced from
strain FCC-3204 was considered to be substantially equivalent to the oil from the strain FCC-1324.
Therefore, it is considered that the strain FCC-3204, subject of the current application, is a valid source
for the NF ‘Schizochytrium sp. oil’ currently authorised on the Union list.
A phylogenetic tree of the Thraustochytriceae family has been reported by the applicant. According to
the applicant, this classification is based on the comparison of sequences of the 18S small subunit of
ribosomal DNA (18S SSU-rDNA). This analysis shows that the strain FCC-1324 (parent strain of FCC-3204)
is close to strain ATCC 20888, which is the source of the currently authorised ‘Schizochytrium sp. oil’.
Upon EFSA’s request for information, the identity of FCC-3204 at species level was addressed by the
applicant based on the comparison of the genome sequence of FCC-1324, which is the parent strain of
FCC-3204, with the genome sequence of the type strain Aurantiochytrium limacinum ATCC MYA-1381
(equivalent to Schizochytrium limacinum ATCC MYA-1381). According to this analysis, average nucleotide
identity (ANI) between the genomes of ATCC MYA-1381 and FCC-1324 was 98.89%, and the two also
have a high degree of collinearity. These data show that the strain FCC-3204 is a member of the species
S. limacinum, which is a synonym of A. limacinum (Morabito et al., 2020).
3.3. Production process
The unicellular microalgae Schizochytrium sp. (FCC-3204) are grown under controlled conditions
(time, temperature, pH and aeration) in a liquid culture medium containing the necessary nutrients.
The cultivation process starts in the laboratory. The production method and the control and verification
processes ensure that the algae used in the production are pure cultures. The water used for the
controlled growth of the microalgae and throughout the production process is food-grade and
conforms to the requirements set out by EU Directive 98/83/CE. The entire process is carried out
under inert atmosphere or vacuum conditions. Quality control evaluations are performed at each stage
of production in accordance with a Hazard Analysis Critical Control Point (HACCP) system and Good
Manufacturing Practice (GMP).
The microalgal biomass is lysed directly via an enzymatic hydrolysis. This lysis involves a food-grade
and non-genetically modified organism (GMO) enzyme. Characteristics of this enzymatic preparation
are provided by the applicant (purity, pH range, temperature activity and temperature of inactivation).
The manufacturer certifies that the production strain of this enzyme is not present in the enzymatic
preparation and that it does not produce toxins. The enzyme was not detected in three batches of the
NF. The crude oil is recovered from the lysed biomass by centrifugation. A clarification step by filtration
is performed to remove solid matter. The crude oil is subsequently refined using standard techniques
(neutralization, decolouration and deodorisation at high temperature). At different steps of the
process, EU-authorised antioxidants are added to ensure stability. The NF is finally packaged in airtight
and light-proof containers and stored at a temperature of –20°C.
The applicant provided data demonstrating that the algal strain Schizochytrium sp. (FCC-3204) does
not produce toxins and data on the absence of viable cells in the NF.
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
The NF produced by the applicant is an oil which may undergo further processing steps (e.g.
powdering) to be used as an ingredient of IF and FOF. However, these steps are not carried out by the
applicant, but by manufacturers of IF and FOF (see also Section 3.4.1 Stability of the NF under the
intended conditions of use). Therefore, the description of the production process ends with the packaging
and storing of the NF in its liquid/oily form.
3.4. Compositional data
The NF consists of triglycerides composed of PUFA in which DHA is the predominant one, making
up together with docosapentaenoic (DPA; n-6) and palmitic acid more than 92% of the total FAs.
In order to confirm that the manufacturing process is reproducible and adequate to produce a
product with the required characteristics on a commercial scale, the applicant provided analytical
information for 5 independent batches of the NF (Table 1). Information was provided on the
accreditation of the laboratories that conducted the analyses presented in the application.
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The proximate analytical results show that the NF is almost entirely composed of crude fat (at least
94%). The applicant provided a new analysis of five independent batches of the NF which reported
contents of proteins below the limit of quantification (LOQ) (0.25%).
The batch-to-batch analysis indicates a good reproducibility of the production process. A slight
variability of certain nutrients (vitamin E, b-carotene, iron) was observed. This was explained by the
use of food additives and processing aids in the refining step. The concentration of total sterols varied
between 9,087 and 13,375 mg/kg, which is in a similar range to that observed in different types of oils
(Yang et al., 2019).
The composition of the NF which is under assessment can be compared to the composition of the
two authorised NFs based on DHA-rich oil from Schizochytrium currently and authorised for uses in IF
and FOF: ‘Schizochytrium sp. (ATCC PTA-9695) oil’ and ‘Schizochytrium sp. (T18) oil’. Compositional
data for these two authorised NFs are available in the dossiers previously assessed by national
authorities and submitted by DSM (2013) and Mara Renewable (2016). A comparison of the main long-
chain (n-3)-PUFA relevant in marine oils (DHA, EPA and DPA) was made. In the present NF, the
average DHA content (65% of FA) is higher compared to the two authorised NFs, in which the DHA
content ranged between 37% and 44% FA. The average EPA content in the present NF (0.74% FA) is
lower compared to the two authorised NFs (6% FA and 1.3% FA). Regarding DPA (n-3) concentration
is low in the present NF (0.24% FA), which is also the case in the two authorised NFs (< 1% FA).
In terms of chemical contaminants, the concentrations of metals (< LOQs), PCBs, dioxins and
polycyclic aromatic hydrocarbons found in this batch-to-batch analysis are within the EU limits
established in the respective regulations and do not present concerns from a safety point of view. Four
batches of the NF were tested for the process contaminants glycidyl fatty acid esters (expressed as
glycidol) and total 3-monochloro-propanol-1,2-diol (MCPD) (free and fatty acid esters). The
Panel notes that for glycidyl fatty acid esters (expressed as glycidol), the maximum level (ML) in IF and
FOF (liquid) is set at 6 lg/kg. For 3-MCPD (sum of 3-MCPD and 3-MCPD fatty acid esters, expressed as
3-MCPD), a ML in IF and FOF (liquid) is set at 15 lg/kg. The MLs for these contaminants are expected
to be respected in the final product (IF and FOF) considering the maximum concentration of the NF in
IF and FOF (63 mg NF/100 mL). The analyses on microbiological contaminants in the NF are presented
in Table 1. Upon EFSA’s request for information, the applicant provided analyses on Enterobacter
sakazakii, which was not detected in five batches of the NF.
The results of analyses in three batches of the NF showed that common marine biotoxins were
below the respective LOQs (diarrhetic shellfish poisoning toxins: LOQ = 20 lg/kg; pectenotoxins:
LOQ = 20 lg/kg; paralytic shellfish poisoning toxins, azaspiracids, yessotoxins, saxitoxin, okadaic acid:
LOQ = 5 lg/kg; domoic acid: LOQ = 1 mg/kg). These data confirm that the NF, produced from
Schizochytrium sp. (strain FCC-3204), is not expected to contain marine biotoxins, neither produced by
the source organism (for which a QPS status was concluded) nor from external contamination
(considering the description of the production process in Section 3.3).
The Panel considers that the information provided on the composition of the NF is sufficient and
does not raise safety concerns.
Table 1: Batch-to-batch analysis of the NF
Parameter (Unit)
Batch number
0403019 0413022 0418028 0419022 0419028
Proximate analysis
Energy (kcal/100 g) 900 900 851 987 851
Fat (g/100 g) > 99.22 > 99.22 > 93.78 > 99.4 > 93.78
Proteins (g/100 g)(a) < 0.5(f) < 0.5(f) < 0.5(f) 0.6 < 0.5(f)
Carbohydrates (g/100 g) < 0.1 < 0.1 < 0.1 < 0.1 < 0.1
Crude ash (g/100 g) < 0.25 < 0.25 < 0.25 < 0.25 < 0.25
Salt (g/100 g) 0.0135  0.0131 0.0390  0.0136 0.0163 
0.0131
< 0.01 0.0250  0.0132
Sodium (g/100 g) 0.005  0.005 0.016  0.005 0.007  0.005 < 0.005 0.011  0.005
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Parameter (Unit)
Batch number
0403019 0413022 0418028 0419022 0419028
Physico-chemical parameters
p-Anisidine value 6.1 2.0 7.3 1.6 5.6
Moisture and volatiles
(%)
< 0.1(g) < 0.1(g) < 0.1(g) < 0.1(g) < 0.1(g)
Unsaponifiable matter
(%)
1.5 1.2 1.4 1.4 1.1
Acid value (mg KOH/g) 0.4 0.2 0.2 0.4 0.5
Peroxide value (meq/kg) 1.7 0.5 1.1 2.1 1.1
Density (kg/L) NA 0.94700 0.9452 
0.0008
0.9493  0.0008 0.9452  0.0008
Relative density NA 0.9487 0.9469 
0.0008
0.9480  0.0008 0.9469  0.0008
Tocopherols (mg/100 g)
a-Tocopherol 26.2 26.2 13.9 26.8 14.1
b-Tocopherol 4.06 4.01 2.05 3.12 2.13
d-Tocopherol 85.8 74.2 39.3 69.5 38.7
c-Tocopherol 195 171 87.5 162 86.3
Sum of tocopherols 311 276 143 262 141
Carotenoids
b-Carotene (lg/100 g) NA < 5 49.1  13.7 < 5 < 5
Lutein and zeaxanthin
(mg/100 g)
NA < 2 < 2 < 2 < 2
Astaxanthin (mg/100 g) NA < 2 < 2 < 2 < 2
Canthaxanthin
(mg/100 g)
NA < 2 < 2 < 2 < 2
Fatty acids (% total FA)
Myristic – 14:0 0.4 0.4 0.6 0.4 0.6
Palmitic – 16:0 13.9 13.3 15.8 12.8 15.8
Margaric – 17:0 NA 0.1 NA NA NA
Heptadecenoic – 17:1 NA 0.2 NA NA NA
Hexadecenoic – 16:1
TOTAL
0.1 0.1 0.1 0.1 0.1
Stearic – 18:0 0.7 0.6 0.7 0.6 0.7
Oleic – 18:1(n-9) 0.3 0.2 0.1 0.1 0.1
cis-Vaccenic – 18:1(n-7) 0.1 0.1 0.1 0.1 0.1
Linoleic – 18:2(n-6) 0.5 0.3 NA 0.1 NA
c-Linolenic – 18:3(n-6) 0.2 0.2 0.1 0.2 0.1
a-Linolenic – 18(n-3) 0.4 0.4 0.2 0.4 0.2
Stearidonic –18:4(n-3) 0.5 0.5 0.3 0.5 0.3
Arachidic – 20:0 0.1 0.1 0.1 0.1 0.1
Homo-c-linolenic – 20:3
(n-6)
0.2 0.2 0.2 0.2 0.2
Arachidonic – 20:4(n-6) 0.4 0.4 0.4 NA 0.4
Eicosatetraenoic – 20:4
(n-3)
0.6 0.6 0.6 0.6 0.6
Eicosapentaenoic
(EPA) – 20:5(n-3)
1.1 0.8 0.5 0.8 0.5
Behenic – 22:0 0.1 0.1 0.1 0.1 0.1
Docosapentaenoic
(DPA) – 22:5(n-6)
13.4 13.3 13.8 13.4 13.9
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Parameter (Unit)
Batch number
0403019 0413022 0418028 0419022 0419028
Docosapentaenoic
(DPA) – 22:5(n-3)
0.3 0.3 0.2 0.2 0.2
Docosahexaenoic
(DHA) – 22:6(n-3)
65.1 66.9 64.2 67.7 64.3
Others unidentified 1.6 0.9 1.9 1.6 1.7




13375 9087 NA NA 9581
Metals (mg/kg)
Mercury < 0.005(f) < 0.005(f) < 0.005(f) < 0.005(f) < 0.005(f)
Cadmium < 0.005(f) < 0.005(f) < 0.005(f) < 0.005(f) < 0.005(f)
Total arsenic < 0.01(f) < 0.01(f) < 0.01(f) < 0.01(f) 0.01 ( 0.003)
Lead < 0.01(f) < 0.01(f) < 0.01(f) < 0.01(f) < 0.01(f)
Copper < 0.05(f) < 0.05(f) < 0.05(f) < 0.05(f) < 0.05(f)




< 1,000 < 1,000 < 1,000 < 1,000 < 1,000
Moulds < 10 < 10 < 10 < 10 < 10
Yeast < 10 < 10 < 10 < 10 < 10
Coliform 30°C < 1 < 1 < 1 < 1 < 1
Thermotolerant
coliforms
< 1 < 1 < 1 < 1 < 1
E. coli b-glucuronidase
positive
< 1 Absence/10 g Absence/10 g Absence/10 g Absence/10 g
Coagulase-positive
staphylococci
< 10(b) Absence/1 g Absence/1 g Absence/1 g Absence/1 g
Sulfite-reducing
anaerobic bacteria
< 1 < 1 < 1 < 1 < 1
Clostridium perfringens < 1 < 1 < 1 < 1 < 1
Bacillus cereus < 10 < 10 < 10 < 10 < 10
Salmonella Absence/25 g Absence/25 g Absence/25 g Absence/25 g Absence/25 g
Listeria monocytogenes Absence/25 g Absence/25 g Absence/25 g Absence/25 g Absence/25 g
Enterobacteria at 30°C < 10 < 10 < 10 < 10 < 10
PCB and dioxins
Sum of dioxin and
furans (PCDD/Fs TEQ)
(pg/g)(c)
NA 0.338 0.337 0.172 0.340
PCB (dioxin like – TEQ)
(pg/g)(c)
NA 0.204 0.204 0.103 0.206
Sum of PCDD/Fs and
dl-PCB – TEQ (pg/g)(c)
NA 0.543  0.136 0.541  0.135 0.275  0.069 0.546  0.137
PCB (total 6 ndl-PCB)
(ng/g)(c)
NA 1.97 1.96 0.992 1.98
Polycyclic aromatic hydrocarbons (lg/kg)
Benzo(a)pyrene NA < 0.5 < 0.5 < 0.5 < 0.5
Benzo(a)anthracene NA < 0.5 < 0.5 < 0.5 < 0.5
Chrysene NA 0.8  0.4 < 0.5 < 0.5 < 0.5
Benzo(b)-fluoranthene NA 0.7  0.5 <0.5 < 0.5 < 0.5
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3.4.1. Stability
Stability of the NF
The applicant performed two stability tests with three independently produced batches of the NF:
one test up to 12 weeks at 25°C and a second test up to 6 months at 40°C. The batches were
regularly analysed for peroxide index (meqO2/kg), p-anisidine value and DHA content (mg/g).
In the 12-week test performed at 25°C, peroxide index increased with time (from 1 to 7.8–9.5
meqO2/kg) and quickly exceeded the value of 5 meqO2/kg (used in the current specifications; see also
Section 3.5). The p-anisidine value increased 26-45% (maximum value 8.7 after 12 weeks).
Concentration of DHA did not change significantly during storage (from 586-601 to 578-586 mg/g).
In the 6-month test at 40°C, peroxide index increased with time (from 1 to 10.6-17.2 meqO2/kg)
and quickly exceeded the value of 5 meqO2/kg (used in the current specifications; see also
Section 3.5). The p-anisidine value considerably increased with a factor of 6–19 (maximum value 45.5
after 6 months of storage). The concentration of DHA remained unchanged (from 586-601 at t = 0 to
562-579 mg/g at t = 6 months).
The results of both studies indicate that the NF is subject to oxidation when stored at 25°C or 40°C. It
is noted that the increase of the oxidation parameters was linear and that the peroxide index was already
above the limit defined by the specification (5 mgeqO2/kg) after 6 weeks of storage at 25°C.
Upon EFSA’s request for information, the applicant indicated that the NF is to be stored at a
temperature at or below –15°C (frozen conditions), away from light, heat and oxygen.
EFSA requested the applicant to provide new stability studies covering the recommended storage
conditions for the NF. Thus, the applicant provided stability studies on four batches of the NF under
the proposed storage conditions (–15°C) as well as at 4°C, 25°C/60% RH and 40°C/75% RH. The
content of DHA and markers of oxidation (peroxide value, p-anisidine value, TOTOX value and acid
value) were analysed regularly during the studies. The markers of oxidation tested were within the
limits set in the specifications (peroxide value < 5.0 meqO2/kg and acid value < 0.5 mg KOH/g) in the
NF batches tested at –15°C and 25°C up to 55 weeks (n = 2) and up to 2 years (n = 2), as well as in
the NF batches (n = 2) tested at 4°C up to 45 weeks and (n = 3) at 40°C up to 24 weeks. The DHA
Parameter (Unit)
Batch number
0403019 0413022 0418028 0419022 0419028
Sum NA 1.5  1.1 NA NA NA
Process contaminants
Glycidyl fatty acid esters
expressed as glycidol
(lg/kg)(d)
NA Not calculable(h) Not calculable(h) Not calculable(h) 22 ( 11)




NA < 100(f) < 100(f) < 100(f) 150 ( 70)
LOD: limit of detection; MCPD: monochloro-propanol-1,2-diol; NA: not analysed; ND: not detected; LOQ: limit of quantification;
PCB: polychlorobiphenyl; dl-PCB: dioxin-like PCB; ndl-PCB: non dioxin-like PCB; PCDD/Fs: polychlorinated dibenzo-p-dioxins and
dibenzofurans; TEQ: toxicological equivalency.
(a): The applicant provided an additional analysis on total nitrogen in 5 independent batches of the NF which contained proteins
below LOQ (0.25%).
(b): A different method was used to analyse this batch as compared to the other batches.
(c): Upper bound results. Upper bound means levels below LOQ (for each congener) are set equal to the LOQ.
(d): It is noted that glycidyl fatty acid esters in infant formulae (IF) should not exceed the maximum level (ML) of 6 lg/kg for
liquid IF and FOF while a maximum concentration of 22 lg/kg was found in batch 0419028. However, considering the
maximum concentration of the NF in IF (63 mg NF/100 mL), the ML of 6 lg/kg in IF is expected to be respected.
(e): It is noted that the sum of 3-MCPD and 3-MCPD esters, expressed as free 3-MCPD in IF should not exceed the maximum
level (ML) of 15 lg/kg for liquid IF and FOF while a maximum concentration of 150 lg/kg (sum expressed as 3-MCPD) was
found in batch 0419028. However, considering the maximum concentration of the NF in IF (63 mg NF/100 mL), the ML of
15 lg/kg in IF is expected to be respected.
(f): LOQ.
(g): LOD.
(h): Glycidyl fatty acid esters were calculated from two parameters ‘total 3-MCPD and glycidyl fatty acid esters’ and ‘3-MCPD
total’. Since both ‘total 3-MCPD and glycidyl fatty acid esters’ and ‘3-MCPD total’ were below LOQ (100 lg/kg) it was not
possible to calculate ‘glycidyl fatty acid esters’.
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content remained above 55% (w/w) in all NF batches tested up to the end of the duration of these
studies. The NF samples were also tested for p-anisidine value and TOTOX value, which remained
within the values indicated by the applicant (p-anisidine value < 20 and TOTOX value < 26) up to the
end of the stability tests. The Panel notes that the p-anisidine value, which indicates the oxidative
stability of the NF, was below 10 throughout the stability tests.
Based on the stability studies provided, the applicant proposed a shelf life for the NF of 2 years
from the date of manufacture, to be stored at a temperature at or below –15°C (frozen conditions),
away from light, heat and oxygen.
The Panel considers that the data provided sufficient information with respect to the stability of the
NF during the proposed shelf life of 2 years.
Stability of the NF under the intended conditions of use (i.e. when the NF oil is powdered
to be incorporated to IF and FOF)
According to the conditions of use proposed by the applicant, the NF is intended to be incorporated
in IF and FOF. The applicant indicated that the NF is micro-encapsulated into a powdered form before
being incorporated into IF and FOF.
During the assessment, EFSA requested information on the stability of the NF when undergoing
processing of powdering into IF and FOF and the storage of the powder. In reply, the applicant
provided the results of the content of DHA and markers of oxidation (peroxide value, p-anisidine value,
TOTOX value and acid value) of three batches of the NF before and after being micro-encapsulated
into a powder form. An increase in the oxidative parameters was observed after the NF being
encapsulated. However, these parameters remained within the specified values (peroxide value < 5.0
meqO2/kg; acid value < 0.5 mg KOH/g; p-anisidine value < 20; TOTOX value < 26). The DHA content,
which remained above 55% (w/w), slightly decreased by 4–5% after the micro-encapsulation.
The Panel notes that the data on oxidative parameters and DHA content relate only to the time
point after processing the NF into powder and did not cover a longer time span. However, considering
the stability data of the NF at 25°C/60% RH up to 2 years, the Panel expects the NF to be stable
under the intended conditions of use (i.e. as a microencapsulated powder and when added to IF and
FOF).
3.5. Specifications
As the NF ‘Schizochytrium sp. oil’ is already authorised on the EU market, specifications for this NF
are currently presented in the Union list. The Panel verified whether the NF under assessment
complies with these specifications and subsequently assessed the need to define further specifications
for the NF under assessment.
Current specifications of the NF (Union list)
Parameters and corresponding values of the current specifications for ‘Schizochytrium sp. oil’ are
reported in Table 2. It is noted that the NF currently authorised is not strain specific. Furthermore, the
microalgae that is the source of the NF under assessment is currently used as a source for the
authorised NF ‘Schizochytrium sp. oil’ (see Section 3.2). Therefore, the NF under assessment shall
comply with the specifications currently defined for ‘Schizochytrium sp. oil’. A comparison with the data
from the batch-to-batch analysis of the present NF is presented in Table 2.
According to the data submitted in the present dossier, the NF produced by the applicant complies
with the current specifications for ‘Schizochytrium sp. oil’.
The maximum values observed in the batch-to-batch analysis for the acid value, peroxide value,
moisture and volatiles, unsaponifiable and trans-FAs are below the limits defined in the specifications
(see Table 2). The results of the storage stability studies indicated that the specifications are expected
to be met when the NF is stored under the proposed conditions of storage (see Section 3.4.1).
The NF under assessment complies with the specifications for ‘Schizochytrium sp. oil’ that is already
authorised on the EU market.
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Discussion on additional specifications for the uses assessed in the present dossier
The applicant used a strain of Schizochytrium sp. (strain FCC-3204) in the production of the NF and
this strain impacts on the FA profile of the NF. Notably, concentrations of DHA range between 64.2%
and 67.7% of the FA content, while the minimum required by the specifications is 32% (w/w).
Therefore, the applicant proposed to amend the current specifications of the Union list to consider this
particularity of the NF. The Panel considers that amending the specification to modify the minimum
concentrations of DHA (i.e. > 55% instead of 32%) is not necessary from a safety point of view.
It is noted that the safety assessment of the NF for its use in IF and FOF required a detailed
analysis of potential contaminants. Most of them are covered by sectoral legislation (e.g. Regulation on
infant formulae). For marine biotoxins, however, risk managers may consider amending the
specifications for the NF ‘Schizochytrium sp. oil’ when authorised in IF and FOF in order to set the
limits at the LOQ achieved in the batch-to-batch analysis.
The Panel notes that the p-anisidine value, which allows monitoring the secondary oxidation of oils,
has not been considered so far on the Union list for Schizochytrium oils. However, secondary oxidation
products (such as a,b-unsaturated carbonyl compounds, malonaldehyde) may be of safety concern
(Kanner, 2007; Vieira et al., 2017). Therefore, the Panel proposes to add the p-anisidine value in the
specifications for Schizochytrium sp. oils. Considering the European Pharmacopoeia values defined for
cod liver and salmon oils (2015) and the compositional data, a maximum limit of 10 could be used for
the p-anisidine value in Schizochytrium oils.
3.6. History of use of the NF and/or of its source
3.6.1. History of use of the source
The source of the NF is a microalgae belonging to the genus Schizochytrium (see full description in
Section 3.2). Table 3 presents the different entries referring to oils from the genus Schizochytrium
which are either currently present in the Union list (Shizochytrium sp.) or have been assessed by EFSA
(Schizochytrium limacinum WZU477).
Table 2: Specifications of the NF (as currently reported in the Union list) and comparison with





NF under assessment (based




≤ 0.5 0.5 (max) Not reported on the UL
Peroxide value
(PV) (meq/kg)
≤ 5.0 2.1 (max) Not reported on the UL
Moisture and
volatile (%)
≤ 0.05 < 0.1 (LOD) Not reported on the UL
Unsaponifiables
(%)
≤ 4.5 1.5 (max) Not reported on the UL
Trans-Fatty acids
(%)
≤ 1.0 < 0.05(a) Not reported on the UL
DHA content (%) ≥ 32.0 64.2–67.7(a) Not reported on the UL
DHA: docosahexaenoic acid; LOD: limit of detection; UL: Union list.
(a): % of fatty acids.
Safety of oil from Schizochytrium limacinum (strain FCC-3204) – IF and FOF
www.efsa.europa.eu/efsajournal 12 EFSA Journal 2021;19(1):6344
This genus has been used as a source of DHA-rich oils since 2003, year of the first authorisation of
the NF DHA-rich oil from Schizochytrium sp. (Commission Decision 2003/427/EC6). The first
assessment of DHA-rich oil from Schizochytrium sp. involved the strain ATCC 2088 (United Kingdom,
2002). However, several other strains have been recognised as valid sources for this NF since 2003.
Following two substantial equivalence assessments (FSAI, 2014 and Anses, 2018), two other strains
(FCC-1324 and FCC-3204, respectively) were recognised as valid sources to produce DHA-rich oils
equivalent to the original NF. On the current Union list, the DHA-rich oils produced from these strains
are commonly referred to as ‘Schizochytrium sp. oil’ under Regulation (EU) 2014/4637. It is noted that
these authorisations currently do not cover the use of these oils in IF and FOF.
Since 2015, two other strains belonging to the genus Schizochytrium were also authorised for the
production of DHA-rich oils: strain ATCC PTA-9695 (2015) and strain T18 (2017). These NFs were also
authorised for use in IF and FOF.
3.6.2. History of use of the NF
DHA-rich oils from Schizochytrium have been on the EU market since 2003. On the Union list, there
are currently four different entries referring to Schizochytrium DHA-rich oils (Table 3).
Table 3: Overview of the entries referring to oils from Schizochytrium sp. which are either currently
present in the Union list or have been assessed by EFSA




Decisions or EFSA opinion Remarks
Schizochytrium sp. oil 2003 Decision 2003/427/EC(a),
2009/778/EC(b), 2014/463/EU(c)
and 2019/109(d)
Schizochytrium sp. oil rich
in DHA and EPA
2012 Authorised by the United Kingdom –
Schizochytrium sp. (ATCC
PTA-9695) oil
2015 Decision 2015/545(e) Authorised use on IF and FOF
Schizochytrium sp. (T18)
oil




EFSA opinion on the safety of oil
from Schizochytrium limacinum
(strain WZU477) for use in infant
and follow-on formula as a novel
food pursuant to Regulation (EU)
2015/2283
Adopted by the NDA Panel on
31/8/2020 (https://doi.org/
10.2903/j.efsa.2020.6242)
DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; IF: infant formulae; FOF: follow-on formulae.
(a): Commission Decision 2003/427/EC: Commission Decision of 5 June 2003 authorising the placing on the market of oil rich in
DHA (docosahexaenoic acid) from the microalgae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No
258/97 of the European Parliament and of the Council. OJ L 144, 16.6.2003, p. 13–14.
(b): Commission Decision 2009/778/EC: Commission Decision of 22 October 2009 concerning the extension of uses of algal oil
from the microalgae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No 258/97 of the European
Parliament and of the Council; OJ L 278, 23.10.2009, p. 56–57.
(c): Commission Implementing Decision 2014/463/EU: Commission Implementing Decision of 14 July 2014 on authorising the
placing on the market of oil from the micro-algae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No
258/97 of the European Parliament and of the Council and repealing Decisions 2003/427/EC and 2009/778/EC; OJ L 209,
16.7.2014, p. 55–58.
(d): Commission Implementing Regulation (EU) 2019/109 of 24 January 2019 authorising an extension of use of Schizochytrium
sp. oil as a novel food under Regulation (EU) 2015/2283 of the European Parliament and of the Council, and amending
Commission Implementing Regulation (EU) 2017/2470; OJ L 23, 25.1.2019, p. 7–10.
(e): Commission Implementing Decision (EU) 2015/545 of 31 March 2015 authorising the placing on the market of oil from the
micro-algae Schizochytrium sp. (ATCC PTA-9695) as a novel food ingredient under Regulation (EC) No 258/97 of the
European Parliament and of the Council; OJ L 90, 2.4.2015, p. 7–10.
6 Commission Decision 2003/427/EC: Commission Decision of 5 June 2003 authorising the placing on the market of oil rich in
DHA (docosahexaenoic acid) from the microalgae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No 258/
97 of the European Parliament and of the Council. OJ L 144, 16.6.2003, p. 13–14.
7 Regulation (EU) 2014/463: Commission Implementing Decision of 14 July 2014 on authorising the placing on the market of oil
from the micro-algae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No 258/97 of the European
Parliament and of the Council and repealing Decisions 2003/427/EC and 2009/778/EC; OJ L 209, 16.7.2014, p. 55–58.
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The NF application under assessment is an extension of use for the oil referred to as generic
Schizochytrium sp. oil that has been authorised since 2003 by means of Commission Decision 2003/427/
EC6. It has been subject to several extensions of use which were reported in Commission Decision 2009/
778/EC8. Commission Implementing Decision 2014/463/EU9 and Commission Implementing Regulation
2019/10910. The NF under assessment (Schizochytrium sp. oil) is currently authorized as a food
supplement (250 mg DHA/day for the general population; 450 mg DHA/day for pregnant and lactating
women) and as a food ingredient in a wide range of food categories (use levels are expressed in mg of
DHA): Milk-based drinks and similar products intended for young children (200 mg/100 g); Processed
cereals-based food and baby foods for infants and young children (200 mg/100 g); Food intended to meet
the expenditure of intense muscular effort (200 mg/100 g); Food-bearing statements on the absence or
reduced presence of gluten (200 mg/100 g); Food for specific medical purposes; Bakery products (breads,
rolls and sweet biscuits) (200 mg/100 g); Cereal bars (500 mg/100 g); Breakfast cereals (500 mg/100 g);
Cooking fats (360 mg/100 g); Dairy analogues except drinks (200-600 mg/100 g); Dairy products except
milk-based drinks (200–600 mg/100 g); Non-alcoholic beverages (including dairy analogue and milk-based
drinks) (80 mg/100 mL); Spreadable fats and dressings (600 mg/100 g); Fruit and vegetables puree
(100 mg/100 g).
Besides the NF under assessment, other Schizochytrium sp. oils are also present on the Union list:
Schizochitrium sp. oil rich in DHA and EPA; Schizochytrium sp. (ATCC PTA-9695) oil and Schizochytrium
sp. (T18) oil. These NFs were authorised for the same food categories as the generic NF
Schizochytrium sp. oil reported above, plus some additional uses. In particular, the two strain-specific
NFs Schizochytrium sp. (ATCC PTA-9695) oil and Schizochytrium sp. (T18) oil were authorised for use
in IF and FOF. These NFs can be used in accordance with Regulation (EU) 609/201311, which was
supplemented by Regulation (EU) 2016/12712.
3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
The NF is intended to be added in IF and FOF. Consequently, the target population defined by the
applicant is infants and young children.
3.7.2. Proposed uses and use levels
The NF is intended to be added to IF and FOF. The proposed use levels are in accordance with
Regulation (EU) No 609/2013 and its supplementing Regulation (EU) 2016/127, which states the
mandatory addition of DHA to IF and FOF at levels ranging between 4.8 and 12 mg/100 kJ (eq.
20–50 mg/100 kcal). Considering a standard energy content of maximum 70 kcal/100 mL of IF/FOF
defined in Regulation (EU) 2016/127, the DHA level in the reconstituted formula is expected to range
between 14 and 35 mg DHA/100 mL. Considering a minimum DHA concentration of 550 mg DHA/g in
the NF, the use level for the NF corresponds to 25–63 mg NF/100 mL, to reach the target of 14–35 mg
DHA/100 mL.
8 Commission Decision 2009/778/EC: Commission Decision of 22 October 2009 concerning the extension of uses of algal oil
from the microalgae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No 258/97 of the European
Parliament and of the Council; OJ L 278, 23.10.2009, p. 56–57.
9 Commission Implementing Decision 2014/463/EU: Commission Implementing Decision of 14 July 2014 on authorising the
placing on the market of oil from the micro-algae Schizochytrium sp. as a novel food ingredient under Regulation (EC) No
258/97 of the European Parliament and of the Council and repealing Decisions 2003/427/EC and 2009/778/EC; OJ L 209,
16.7.2014, p. 55–58.
10 Commission Implementing Regulation (EU) 2019/109 of 24 January 2019 authorising an extension of use of Schizochytrium
sp. oil as a novel food under Regulation (EU) 2015/2283 of the European Parliament and of the Council, and amending
Commission Implementing Regulation (EU) 2017/2470; OJ L 23, 25.1.2019, p. 7–10.
11 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council
Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of
the European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009 Text with
EEA relevance; OJ L 181, 29.6.2013, p. 35–56.
12 Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the
European Parliament and of the Council as regards the specific compositional and information requirements for infant formula
and follow-on formula and as regards requirements on information relating to infant and young child feeding; OJ L 25,
2.2.2016, p. 1–29.
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It should be noted that manufacturers of IF and FOF who may powder the NF and incorporate it
into their formulae shall guarantee that the concentration of DHA meets the requirement of the
Regulation. This is also the case if other sources of DHA are used in combination with the NF.
3.7.3. Anticipated intake of the NF
As the proposed use levels are in accordance with Regulation (EU) No 609/2013 and its
supplementing Regulation (EU) 2016/127, the intake of DHA for infants fed with IF supplemented with
the NF at the proposed use level is within the range foreseen by the Regulation.
The Panel assessed the maximum intake of NF resulting from the use of the NF in IF. The
conservative scenario where IF is the only food consumed by non-breastfed infants from 0 to 4
months was considered, using the default value of 260 mL/kg body weight (bw) per day for high
formula intakes for infants 0–4 months (EFSA Scientific Committee, 2017). Based on the use level
defined by the applicant (maximum concentration of NF in IF of 63 mg/100 mL), the high intake of NF
resulting from the consumption of IF is estimated to be 163.8 mg NF/kg bw per day.13 Considering
that 55% of the NF is DHA, the estimated high daily intake of DHA from IF is 90 mg/kg bw per day.
Furthermore, two other DHA-rich oils from Schizochytrium14 are currently already authorized for use
in IF and FOF, with use levels also in line with Regulation (EU) 2016/127. Consequently, the intended
use of IF and FOF currently under assessment for the NF Schizochytrium sp. oil (from strain FCC-3204)
is not expected to modify the current daily intake of DHA-rich oil for infants and young children. The
NF is proposed by the applicant as an alternative source of DHA for IF and FOF.
3.8. Absorption, distribution, metabolism and excretion (ADME)
The applicant did not submit specific ADME data for the NF. Digestion, absorption and metabolism
of DHA have been extensively documented in the EFSA Scientific Opinion on Tolerable Upper Intake
Level of EPA, DHA and DPA (EFSA NDA Panel, 2012).
3.9. Nutritional information
The nutritional content of the NF is provided by the batch-to-batch analysis. The NF mainly consists
of fat in the form of triglycerides. trans-FAs were not detected, and based on the acid value, free FAs
are not expected to be of concern. The FA profile reveals that DHA is the predominant compound.
DHA is an essential nutrient for infants and children. The essential role of DHA for the development of
the nervous system and the retina in infants and young children has been documented in the EFSA
Scientific Opinion on nutrient requirements and dietary intakes of infants and young children in the
European Union (EFSA NDA Panel, 2013). When used in accordance with the proposed use level, the
NF can enrich the composition of IF and FOF to such extent that the latter fall within the range
targeted by the current Regulation (20–50 mg DHA/100 kcal).
The concentration of sterols in the NF ranges between 9,000 and 13,400 mg/kg and corresponds to
0.0057–0.0084 mg/mL in IF and FOF added with 63 mg NF/100 mL. The concentration of sterols in IF
and FOF added with the NF is below the concentration of sterols reported in marketed IF and FOF
(total animal sterols: 0.017–0.054 mg/mL; total plant sterols: 0.03–0.05 mg/mL reported by
Claumarchirant et al., 2015; total sterols: 0.09–0.15 mg/mL reported by Hamdan et al., 2018).
The analysis of the composition shows the presence of other nutrients such as sodium, vitamin E,
beta-carotene. However, given that the NF will be incorporated into IF and FOF at a maximum
concentration of 63 mg NF/100 mL, the presence of those nutrients in the reconstituted formulae is
not expected to be of health concern.
The analysis of the FA profile of the NF shows the presence of other components that might affect
the overall ratio of FA in IF and FOF. However, it falls under the responsibility of the manufacturers to
guarantee that the overall ratio of FA complies with the current regulations.
The Panel considers that, taking into account the composition of the NF and the proposed
conditions of use, consumption of the NF is not nutritionally disadvantageous.
13 The mean body weight of a 0- to 3-month infant is 5 kg and is used as a default body weight for the whole group of infants
(EFSA Scientific Committee, 2012).
14 Schizochytrium sp. (ATCC PTA-9695) oil and Schizochytrium sp. (T18) (see Section 3.6.2).
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3.10. Toxicological information
3.10.1. Qualified presumption of safety (QPS)
The available evidence indicates that the source organism (Schizochytrium sp., strain FCC-3204)
belongs to the species S. limacinum. In 2020, S. limacinum was assessed by the EFSA Panel on
Biological Hazards (BIOHAZ) for its suitability to be added to the list of QPS-recommended biological
agents intentionally added to food or feed. In the opinion of the BIOHAZ Panel, S. limacinum was
identified as a synonym of A. limacinum. The BIOHAZ Panel considered the identity, the body of
knowledge and potential safety concerns of this microorganism. The literature searches performed did
not provide any evidence for a safety concern for human or animal health for any use of S. limacinum.
The BIOHAZ Panel concluded that S. limacinum is recommended for the QPS list with the qualification
‘for production purposes only’ (EFSA BIOHAZ Panel, 2020).
3.10.2. Absence of marine biotoxins
The absence of marine biotoxins was demonstrated in the assessment of the composition of the NF
(see Section 3.4). The Panel investigated whether the LOQs used in the reported analysis of the
common marine biotoxins were sufficiently low compared to the acute reference dose (ARfD) of the
respective biotoxins (EFSA CONTAM Panel, 2009). It was found that the theoretical intakes resulting
from the occurrence of marine biotoxins at their respective LOQs remained well below the respective
ARfD of the corresponding biotoxins. It is concluded that the reported LOQs are sufficiently low to
ensure consumer safety.
3.10.3. Toxicity of DHA-oils derived from Schizochytrium sp.
No toxicity studies that were conducted with the NF under assessment (DHA-rich oil produced from
strain FCC-3204 of Schizochytrium sp.) have been provided by the applicant.
However, the toxicity of DHA-rich algal oils produced from different strains of Schizochytrium sp.
has been extensively investigated over the last decades. Several guideline-compliant studies, including
bacterial reverse mutation tests, in vitro chromosomal aberration tests, in vivo mammalian cell
micronucleus tests, subchronic toxicity studies with rats, and developmental and reproductive toxicity
studies with rats, were performed with various forms of DHA algal oils from Schizochytrium sp. Most of
these studies were assessed and used to conclude on the safety of NFs evaluated in former
authorisation frameworks. Notably two studies performed with DHA-oil produced from strain ATCC
PTA-9695 (Fedorova-Dahms et al., 2011 and an unpublished study) were performed to support the
authorisation of the NF Schizochytrium sp. (ATCC PTA-9695) in infant and follow-on formula. These
studies have been assessed by the UK competent authority in 2014 (United Kingdom, 2014). Similarly,
two other studies performed with DHA-oil produced from strain T18 (Schmitt et al., 2012a,b) have also
been considered by the UK competent authority in support of the authorisation of the NF
Schizochytrium sp. (T18) in infant and follow-on formula in 2017 (United Kingdom, 2017). In addition,
two other studies (Lewis et al., 2016; Falk et al., 2017), performed with DHA-oils from unspecified
strains of Schizochytrium sp., have been considered in the assessment carried out by Anses (2018).
In all previous assessments, the competent authorities concluded that there were no concerns with
regard to genotoxicity and subchronic toxicity of the tested materials. Further studies found in the
literature indicate the same outcome for a diversity of DHA-oils produced from other strains of
Schizochytrium sp. which have a longer history of use (Hammond et al., 2001a, 2001b, 2002; Blum
et al., 2007; Kroes et al., 2003; Abril et al., 2003).
3.10.4. Summary
Even though toxicological tests were not conducted with the NF that is assessed in the present
opinion, the Panel considers that, given the results on toxicity in studies performed with various forms
of DHA-rich oils derived from Schizochytrium sp., given the QPS status of the source of the NF, and
considering data on the production process and on the composition of the NF and the absence of
viable cells, there are no concerns with regard to toxicity of the NF.
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3.11. Allergenicity
Upon EFSA’s request for information, the applicant provided a new analysis of five batches of the
NF, which indicated that proteins were below the LOQ (0.25%). The Panel considers that the NF is
unlikely to trigger adverse allergic reactions in the general population or subgroups thereof under the
proposed conditions of use.
4. Discussion
The NF, which is the subject of the application, is a DHA-rich oil derived from Schizochytrium sp.
(FCC-3204). The available evidence indicates that the source organism (Schizochytrium sp., strain FCC-
3204) belongs to the species S. limacinum. The source organism which is assessed in this application
is S. limacinum (FCC-3204) and not the generic Schizochytrium sp. The Panel considers that the
information provided on the composition of the NF is sufficient and does not raise safety concerns.
In 2020, S. limacinum was assessed by the EFSA BIOHAZ Panel and attributed the QPS status with the
qualification ‘for production purposes’, which implies the absence of viable Schizochytrium cells in the final
product. Data provided by the applicant demonstrated the absence of viable cells in the NF. The
Panel considers that the production process is sufficiently described and does not raise safety concerns.
The applicant intends to market the NF as an ingredient for IF and FOF to meet the requirement of
Regulation (EU) 2016/127. Consequently, the proposed use levels (defined on DHA basis) are the same
as for the other DHA-rich oils from Schizochytrium sp. which are currently on the market and
authorised for supplementing DHA in IF and FOF. Therefore, the intake of DHA resulting from the
proposed use is not expected to modify the current situation as regards the total intake of DHA in
infants and young children.
Toxicological tests with the NF were not performed. However, based on the available toxicological
data of various forms of DHA-oils derived from Schizochytrium sp., the QPS status of the source of the
NF, the production process, the composition of the NF and absence of viable cells in the NF, the
Panel considers that there are no concerns with regard to toxicity of the NF.
5. Conclusions
The Panel concludes that the NF, i.e. Schizochytrium sp. oil (produced from the strain FCC-3204
belonging to species S. limacinum is safe under the proposed conditions of use. The target population
is infants and young children.
6. Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on the safety of Schizochytrium sp. oil as a novel food Ref.
Ares(2019)3149182, dated 13 May 2019.
2) On 13/05/2019, a valid application on Schizochytrium sp. oil as a novel food, which was submitted
by Fermentalg, was made available to EFSA by the European Commission through the Commission
e-submission portal (NF 2019/0825) and the scientific evaluation procedure was initiated.
3) On 18/11/2019, EFSA requested the applicant to provide additional information to
accompany the application and the scientific evaluation was suspended.
4) On 07/09/2020, additional information was provided by the applicant and the scientific
evaluation was restarted.
5) During its meeting on 24 November 2020, the NDA Panel, having evaluated the data,
adopted a scientific opinion on the safety of oil from S. limacinum (strain FCC-3204) for use
in infant and follow-on formula as a NF pursuant to Regulation (EU) 2015/2283.
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Abbreviations
ADME absorption, distribution, metabolism and excretion
AI adequate intake
ANI Average nucleotide identity
ARfD acute reference dose
ATCC American Type Culture Collection
BIOHAZ Panel on Biohazards
bw body weight
CCAP Culture Collection of Algae and Protozoa
CFU colony forming unit






GMO genetically modified organism
GMP Good Manufacturing Practice
HACCP Hazard Analysis Critical Control Point
IF infant formula
LOD limit of detection
LOQ limit of quantification
MCPD monochloro-propanol-1,2-diol
ML maximum level
NDA Panel on Nutrition, Novel Foods and Food Allergens
NF novel food
PCB polychlorobiphenyl
PUFA polyunsaturated fatty acids
PV peroxide value
QPS qualified presumption of safety
rDNA ribosomal DNA
RH relative humidity
SAMS Scottish Marine Institute
TG triglyceride
TEQ toxicological equivalency
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